Cardiome Pharma Corp. (USA) (NASDAQ:CRME)

CAPS Rating: 3 out of 5

Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.

Recs

0
Player Avatar hiddenflem (77.70) Submitted: 1/9/2012 1:29:13 PM : Outperform Start Price: $2.62 CRME Score: -14.08

Have long liked their lead compound. This should be a good year for cardiome-the partnership with Merck is great news.

Featured Broker Partners


Advertisement